JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

Mostrar otras versiones (1)

BACKGROUND: The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed. Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales: Walz, Lucas, Cohen, Avi J., Rebaza, Andre P., Vanchieri, James, Slade, Martin D., Dela Cruz, Charles S., Sharma, Lokesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797881/
https://www.ncbi.nlm.nih.gov/pubmed/33430799
http://dx.doi.org/10.1186/s12879-020-05730-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797881/
https://www.ncbi.nlm.nih.gov/pubmed/33430799
http://dx.doi.org/10.1186/s12879-020-05730-z

Ejemplares similares